| Beyond ANOVA and MANOVA for repeated measures: Advantages of generalized estimated equations and generalized linear mixed models and its use in neuroscience research MB de Melo, D Daldegan‐Bueno, MG Menezes Oliveira, AL de Souza European Journal of Neuroscience 56 (12), 6089-6098, 2022 | 63 | 2022 |
| ‘Resurgent’, ‘twin’ or ‘silent’ epidemic? A select data overview and observations on increasing psycho-stimulant use and harms in North America B Fischer, C O’Keefe-Markman, A Lee, D Daldegan-Bueno Substance Abuse Treatment, Prevention, and Policy 16 (1), 17, 2021 | 52 | 2021 |
| LSD and creativity: Increased novelty and symbolic thinking, decreased utility and convergent thinking I Wießner, M Falchi, LO Maia, D Daldegan-Bueno, F Palhano-Fontes, ... Journal of Psychopharmacology 36 (3), 348-359, 2022 | 41 | 2022 |
| Identifying risk-thresholds for the association between frequency of cannabis use and development of cannabis use disorder: A systematic review and meta-analysis T Robinson, MU Ali, B Easterbrook, S Coronado-Montoya, ... Drug and Alcohol Dependence 238, 109582, 2022 | 40 | 2022 |
| Ayahuasca's therapeutic potential: What we know–and what not LO Maia, D Daldegan-Bueno, I Wießner, DB Araujo, LF Tófoli European Neuropsychopharmacology 66, 45-61, 2023 | 38 | 2023 |
| The ritual use of ayahuasca during treatment of severe physical illnesses: a qualitative study LO Maia, D Daldegan-Bueno, LF Tófoli Journal of psychoactive drugs 53 (3), 272-282, 2021 | 33 | 2021 |
| Opioid use, regulation, and harms in Brazil: a comprehensive narrative overview of available data and indicators LO Maia, D Daldegan-Bueno, B Fischer Substance Abuse Treatment, Prevention, and Policy 16, 1-10, 2021 | 29 | 2021 |
| Toward a “Post-Legalization” Criminology for Cannabis: A Brief Review and Suggested Agenda for Research Priorities B Fischer, D Daldegan-Bueno, P Reuter Contemporary Drug Problems 48 (1), 58-74, 2021 | 27 | 2021 |
| Facing the option for the legalisation of cannabis use and supply in New Zealand: An overview of relevant evidence, concepts and considerations B Fischer, D Daldegan‐Bueno, JM Boden Drug and alcohol review 39 (5), 555-567, 2020 | 26 | 2020 |
| Ayahuasca and tobacco smoking cessation: results from an online survey in Brazil D Daldegan-Bueno, LO Maia, CM Massarentti, LF Tófoli Psychopharmacology 239 (6), 1767-1782, 2022 | 23 | 2022 |
| Systematic review of psychometric instruments used in research with psychedelics AA de Deus Pontual, HG Senhorini, CM Corradi-Webster, LF Tófoli, ... Journal of Psychoactive Drugs 55 (3), 359-368, 2023 | 22 | 2023 |
| The current state of ayahuasca research in animal models: A systematic review D Daldegan-Bueno, NM Simionato, VM Favaro, LO Maia Progress in Neuro-Psychopharmacology and Biological Psychiatry 125, 110738, 2023 | 12 | 2023 |
| Co-exposure of cocaine and cannabinoids and its association with select biological, behavioural and health outcomes: A systematic scoping review of multi-disciplinary studies D Daldegan-Bueno, LO Maia, M Glass, D Jutras-Aswad, B Fischer European Neuropsychopharmacology 51, 106-131, 2021 | 12 | 2021 |
| Effects of repeated ayahuasca administration on behaviour and c-Fos expression in male rats exposed to the open field D Daldegan-Bueno, VM Favaro, PR Morais, A Sussulini, MGM Oliveira Behavioural brain research 427, 113878, 2022 | 11 | 2022 |
| Co-exposure of cannabinoids with amphetamines and biological, behavioural and health outcomes: a scoping review of animal and human studies D Daldegan-Bueno, LO Maia, M Glass, D Jutras-Aswad, B Fischer Psychopharmacology, 1-20, 2021 | 11 | 2021 |
| New Zealand’s ‘Cannabis Legalisation and Regulation Bill’: an evidence-based assessment and critique of essential regulatory components towards policy outcomes B Fischer, D Daldegan‐Bueno New Zealand Medical Journal 133 (1519), 103-111, 2020 | 11 | 2020 |
| Psychosocial and Drug Use Assessment of Regular vs. Non-Regular Ayahuasca Users in a Brazilian Sample: a Web-Based Survey D Daldegan-Bueno, D Révész, PR Morais, PCR Barbosa, LO Maia Substance Use & Misuse 57 (7), 1072-1081, 2022 | 10 | 2022 |
| Why comparative epidemiological indicators suggest that New Zealand is unlikely to experience a severe opioid epidemic B Fischer, O Caroline, D Daldegan-Bueno, C Walters International Journal of Drug Policy 93, 103166, 2021 | 10 | 2021 |
| Conceptualizing and considering Cannabis-Related “Harm-to-Others”: The Role of Cannabis-Related Violence D Daldegan-Bueno, SR Lindner, B Fischer Substance Use & Misuse 57 (9), 1488-1491, 2022 | 9 | 2022 |
| Comparison of crude population-level indicators of opioid use and related harm in New Zealand and Ontario (Canada) B Fischer, D Daldegan-Bueno, W Jones Pain and Therapy 10 (1), 15-23, 2021 | 5 | 2021 |
Lucas Oliveira MaiaBrain Institute, UFRNایمیل تأیید شده در ufrn.edu.br